Along with the imaging lab, Median will provide biopharmaceutical companies with new decision-making tools for clinical trials using data mining and artificial intelligence (AI) technology from iBiopsy® and Radiomix.
Imaging lab solutions will support the paradigm shift in the pharmaceutical industry to create therapies aimed at patients with early-stage cancer.
The Imaging Lab team will perform at the ASCO Annual Conference, Chicago June 3-7, 2022, at Media Booth # 2098, Exhibition Hall, McCormick Place.
Sophia Antipolis, France – (Business Wire) – Regulatory News:
Median Technologies (Paris: ALMDT) announced today that the company is expanding its service portfolio with Imaging Lab, a new entity aimed at leveraging technology from radiology to use imaging data from clinical trials in oncology to take advantage of technology in radiomix.
The creation of imaging labs implements integration into iCRO’s activities to develop medical device software for early diagnosis of cancer, especially for the development of new drugs for oncology and iBiopsy® for early detection of cancer. Date, lung cancer.
“We are seeing a shift in the paradigm, with pharmaceutical companies creating more and more new drug candidates targeting patients with early-stage cancer.”Frederick Bragg is the CEO and founder of Median Technologies. “Coordination between our iCRO and iBiopsy activities3 Perfect to respond to this change: iBiopsy3 Integrates AI technologies to create medical device software that makes it possible for patients to diagnose pathologies at a very early stage without symptoms. At the same time, iCRO has a great deal of knowledge about image processing and its management in clinical trials. The cross-fertilization of our two activities together with other clinical data will enable us to absorb imaging data in an unparalleled way and provide biopharmaceutical company tools for Go / NoGo decision testing. “Frederick Bragg added.
Specifically, imaging lab conditioning success in clinical trials will provide new answers on four axes: selection of patients included in the trial, especially those included in the early stages of the disease, thanks to AI technology, response prediction therapy, disease progression safety measures and progress . The aim is to optimize clinical development plans for drug candidates, especially to facilitate Go / No-Go decisions to increase the success rate of clinical trials. This rate is particularly low in oncology, creating an average development cost of 2. 2.8 billion for marketing a new molecule, compared to an average of বিল 1 billion per new molecule marketed to others.1.
” Based on our experience with image management in clinical trials, we find that trial data has been widely used. We can extract more information from images through the extensive use of data mining, AI and radiomix, and with the help of these technologies we can best help our customers and biopharmaceutical partners in their development. The clinic, “said Nicholas Dano, ICRO, COO of Median Technologies.
The Imaging Lab team will meet at the ASCO Annual Conference (Art Exhibition Date) in Chicago on June 4-6 at Booth # 2098 Exhibit Hall to meet with the pharmaceutical community.
About Media Technology: Median Technologies provides innovative software solutions and imaging services to advance healthcare for all. We harness the power of the medical image using the most advanced artificial intelligence technology to enhance the accuracy of diagnosis and treatment of many cancers and metabolic diseases and to contribute to the emergence of new therapies for patients. Our iCRO solution for analyzing and managing medical images in oncology clinical trials and iBiopsy®, our medical device software based on AI technology helps biopharmaceutical companies and physicians to offer new treatments to patients and earlier and more accurate diagnoses. In this way, we contribute to a healthier world.
Created in 2002, with a subsidiary in the United States in Sophia Antipolis, France, and another in Shanghai, Median has been labeled an “innovative company” by BPI Finance and listed on the Euronext Growth Market (Paris) -ISIN code: FR0011049824: . Eligible for the Median PEA PME, Enternext® appears on the PEA-PME 150 Index and is labeled European Rising Tech by Euronext. More information at www.mediantechnologies.com
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88
Press – ALIZE RP
+33 6 64 18 99 59
Investor – ACTIFIN
+33 6 21 10 49 24